Last updated on April 2019

MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Lymphoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Angiocentric T-cell lymphoma
  • Age: Between 15 - 70 Years
  • Gender: Male or Female

Inclusion Criteria:

Pathological diagnosis of extranodal natural killer/T-cell lymphoma, nasal type based on WHO 2008 classification of tumors of haematopoietic and lymphoid tissue.

Eastern Cooperative Oncology Group (ECOG ) performance status 0~3.

Stage IV disease with at least one measurable lesion.

Preserved organ functions for: Platelet>20109/L, hemoglobin>60g/L, total bilirubin (TBIL)<5ULN, alanine transaminase (ALT)<5ULN, normal serum creatinine, fibrinogen0.5g/L, LVEF50%.

No history of chemotherapy or radiotherapy for other solid cancers.

Signed Informed consented.

Exclusion Criteria:

Relapsed or progressive disease within 6 months of prior L-asparaginase-based chemotherapy.

Concurrent cancers need surgery or chemotherapy within 6 months.

History of radiotherapy of upper-aero-digestive tract within last 3 months.

Significant complications: LVEF50%, coagulopathy, autoimmune disease, severe infection, or liver cirrhosis, hemophagocytic lymphohistiocytosis.

Mental disorders.

Pregnant or lactation.

HIV, hepatitis virus C (HCV), or active hepatitis virus B (HBV) infection with HBV DNA105 copies/ml.

History of pancreatitis.

Known history for grade 3/4 allergy to the drugs in chemotherapy regimen.

Enrolled in other trial treatment.

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.